“Towards Viksit Bharat: TDB enables Startup to Redefine Pneumonia Treatment”

In line with the Prime Minister’s vision of Atmanirbhar Bharat and contributing to India’s aspiration of becoming a global leader in affordable healthcare technologies, the Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to M/s Aodh Lifesciences Pvt. Ltd., Hyderabad for development of Indigenous Antibiotic Nebulization Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

The novel technology represents a paradigm shift in antibiotic delivery. Unlike conventional oral or intravenous therapies, AONEUM-04 enables direct, localized delivery of Antibioticthrough nebulization, ensuring higher drug concentration at the site of infection in the lungs while reducing systemic side effects. Its unique formulation combines sustained release, strong mucoadhesion, and biofilm disruption capabilities, thereby enhancing efficacy and reducing the likelihood of antibiotic resistance. This makes it particularly relevant for India, where pneumonia is a leading cause of child mortality and AMR is a fast-emerging healthcare crisis.

The innovation has successfully cleared pre-clinical trials and will undergo Phase III clinical trials before commercialization. With a demonstrated ability to improve treatment compliance and affordability, the technology holds promise not only for India but also for global markets.

Speaking on the occasion, Sh. Rajesh Kumar Pathak, Secretary, TDB, said, “This project represents a significant stride in addressing pneumonia and antimicrobial resistance, two pressing healthcare challenges in India and worldwide. By supporting indigenous innovation like AONEUM-04, TDB is reinforcing India’s capability to deliver affordable, scalable, and globally relevant healthcare solutions.”

The promoters of Aodh Lifesciences Pvt. Ltd. added, “With TDB’s support, we are poised to advance AONEUM-04 through final clinical trials and bring a truly patient-centric antibiotic therapy to market. Our mission is to make effective, safe, and affordable treatments accessible to the masses while contributing to the global fight against antimicrobial resistance.”